ribonuclease A family member 4Genealiases: RAB1 · RNS4
Q-omics provides the consensus-scored RNASE4 profile across patient tissues and cancer cell-line models. RNASE4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNASE4 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, RNASE4 protein abundance shows 22,029 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where RNASE4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE4 survival associations across molecular data types. RNASE4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE4 RNA expression–survival associations across cancer types. High RNASE4 expression shows unfavorable associations in ACC and LGG, but favorable associations in KIRC, SKCM, UVM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNASE4 RNA expression.
This table summarizes RNASE4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RNASE4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE4 shows lower tumor expression in KICH, LUAD, LUSC, BLCA and LIHC and higher tumor expression in KIRC. The KICH box plot shows higher RNASE4 RNA expression in normal versus tumor tissue (log2 FC = −1.789, t-test p < 0.001).
This table shows molecular features associated with RNASE4 in patient tissues and cancer cell lines. In patient samples, RNASE4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
